Literature DB >> 6712868

Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy.

M B Finch, G D Johnston, J G Kelly, D G McDevitt.   

Abstract

The effects of maintenance indomethacin therapy on single dose digoxin pharmacokinetics and dynamics were studied in six healthy volunteers with normal renal function. Indomethacin did not alter the elimination half-life, systemic clearance or distribution of digoxin. No pharmacodynamic interaction as assessed by changes in the systolic time intervals QA2 and LVET was found. This study does not lend support for a significant digoxin-indomethacin interaction in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712868      PMCID: PMC1463372          DOI: 10.1111/j.1365-2125.1984.tb02353.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  The effect of indomethacin on renal function in pentobarbital-anesthetized dogs.

Authors:  L P Feigen; E Klainer; B M Chapnick; P J Kadowitz
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

2.  Dependency of renal blood flow on prostaglandin synthesis in the dog.

Authors:  A J Lonigro; H D Itskovitz; K Crowshaw; J C McGiff
Journal:  Circ Res       Date:  1973-06       Impact factor: 17.367

3.  Interactions with digoxin: more problems.

Authors:  C F George
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

4.  Effects of selected drugs on serum digoxin concentration in dogs.

Authors:  R D Wilkerson; P B Mockridge; G K Massing
Journal:  Am J Cardiol       Date:  1980-06       Impact factor: 2.778

5.  Toxic digitalis levels associated with indomethacin therapy in a neonate.

Authors:  M S Schimmel; R J Inwood; A I Eidelman; U Eylath
Journal:  Clin Pediatr (Phila)       Date:  1980-11       Impact factor: 1.168

6.  Prostaglandin control of renal circulation in the unanesthetized dog and baboon.

Authors:  J A Swain; G R Heyndrickx; D H Boettcher; S F Vatner
Journal:  Am J Physiol       Date:  1975-09

7.  Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man.

Authors:  P Negus; R L Tannen; M J Dunn
Journal:  Prostaglandins       Date:  1976-08

8.  The effect of indomethacin on kidney function and plasma renin activity in man.

Authors:  A J Donker; L Arisz; J R Brentjens; G K van der Hem; H J Hollemans
Journal:  Nephron       Date:  1976       Impact factor: 2.847

  8 in total
  8 in total

1.  Interaction between digoxin and indomethacin or ibuprofen.

Authors:  H S Jørgensen; H R Christensen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 5.  Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.

Authors:  G Koren
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

Review 6.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 7.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 8.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.